# White House Withdraws FDA Commissioner Nominee

The White House withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration before the Senate Health, Education, Labor and Pensions Committee held a vote, leaving the FDA without a permanent commissioner and deferring the confirmation decision to the next Congress. The leadership gap could add uncertainty to FDA priorities and regulatory decisions, including its mifepristone safety review. The signal identifies no contract, solicitation, or direct procurement opportunity.

- FDA contractors and suppliers should not treat the nomination withdrawal as a change to a specific solicitation or contract; none is identified in the signal.
- For organizations whose work depends on FDA priorities or regulatory decisions, the lack of a permanent commissioner may create uncertainty in planning, but the signal specifies no procurement timeline or requirement.
- Senator Josh Hawley said Overton committed to using private commercial data, including insurer data, where necessary. This may be relevant to firms that provide such data, but no procurement action is announced.

**Jurisdictions:** federal
**Industries:** Healthcare
**Published:** November 20, 2026

### Government Entities
- Food and Drug Administration (FDA)
- U.S. Senate
- Senate Committee on Health, Education, Labor and Pensions (HELP Committee)
- White House

### Key Quotes
> She commits to using private commercial data, including insurer data, where necessary to provide a complete picture, which is something I've been pushing for.
> — Josh Hawley, U.S. Senator

### Sources
- [FDA will have to wait for a permanent commissioner as Trump withdraws nominee - Government Executive](https://www.govexec.com/management/2026/11/white-house-pulls-fda-nominee-leaving-agency-without-permanent-leader/417345) - Government Executive